PTHrP promotes subchondral bone formation in TMJ-OA

Area of Science:

• Biochemistry
• Cell Biology
• Orthopedics

Background:

• Temporomandibular joint osteoarthritis (TMJ-OA) involves complex signaling pathways.
• The roles of parathyroid hormone-related peptide (PTHrP) and transforming growth factor-β (TGFβ) in TMJ-OA pathogenesis are not fully understood.
• Disordered occlusion is a common cause of TMJ-OA.

Purpose of the Study:

• To investigate the therapeutic potential of PTHrP in a TMJ-OA animal model.
• To elucidate the underlying molecular mechanisms of PTHrP action in TMJ-OA, focusing on bone remodeling and TGFβ signaling.

Main Methods:

• Established a TMJ-OA animal model using disordered occlusion.
• Administered intermittent PTHrP (iPTH) to model animals.
• Utilized immunohistochemistry, histology, Micro-CT, histomorphometry, Western Blot, and in vitro cell culture (mesenchymal stem cells) to analyze condylar changes, bone formation, and signaling pathways.

Main Results:

• iPTH treatment significantly reduced condylar cartilage degeneration in TMJ-OA model animals.
• iPTH promoted subchondral bone formation by increasing osteoblast differentiation (OSX, OCN positive cells) and osteoclast numbers, leading to increased bone volume.
• In vitro, PTHrP enhanced osteoblastic differentiation of mesenchymal stem cells and inhibited TGFβ signaling, while PTHrP-PTH1R signaling suppressed TGFβ signaling during osteoblastic differentiation.

Conclusions:

• Intermittent PTHrP administration is effective in improving TMJ-OA lesions by enhancing subchondral bone osteoblastic differentiation.
• PTHrP exerts its therapeutic effects, in part, by suppressing aberrant TGFβ signaling.
• PTHrP targeting the TGFβ pathway represents a promising biological reagent for preventing and treating TMJ-OA.